Platinum Investment Management Ltd. decreased its position in shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) by 8.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,286,032 shares of the biotechnology company’s stock after selling 125,800 shares during the quarter. Platinum Investment Management Ltd.’s holdings in Infinity Pharmaceuticals were worth $2,610,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of INFI. Ameriprise Financial Inc. bought a new stake in Infinity Pharmaceuticals during the second quarter worth about $130,000. JPMorgan Chase & Co. bought a new stake in Infinity Pharmaceuticals during the third quarter worth about $135,000. Alambic Investment Management L.P. bought a new stake in Infinity Pharmaceuticals during the fourth quarter worth about $158,000. Wells Fargo & Company MN lifted its position in Infinity Pharmaceuticals by 654.7% during the fourth quarter. Wells Fargo & Company MN now owns 105,136 shares of the biotechnology company’s stock worth $213,000 after purchasing an additional 91,206 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Infinity Pharmaceuticals by 102.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 150,375 shares of the biotechnology company’s stock worth $305,000 after purchasing an additional 75,980 shares during the period. 50.69% of the stock is owned by institutional investors and hedge funds.
Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) opened at $2.75 on Thursday. Infinity Pharmaceuticals Inc. has a 52-week low of $0.93 and a 52-week high of $3.75.
Separately, ValuEngine cut shares of Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st.
TRADEMARK VIOLATION NOTICE: “Infinity Pharmaceuticals Inc. (INFI) Position Trimmed by Platinum Investment Management Ltd.” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/15/infinity-pharmaceuticals-inc-infi-position-trimmed-by-platinum-investment-management-ltd.html.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Want to see what other hedge funds are holding INFI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Infinity Pharmaceuticals Inc. (NASDAQ:INFI).
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.